# TAGRISSO® (osimertinib) HCP

- **Website:** <https://tagrissohcp.com>
- **Primary alias:** `tagrissohcp.com`
- **Employees:** 2+
- **Company kind:** PRIVATELY HELD

## Description

TAGRISSO® is a renowned brand that offers targeted therapy for both resectable and metastatic EGFRm non-small cell lung cancer (NSCLC). With its innovative and effective treatments, TAGRISSO® has become the first-line treatment choice for metastatic EGFRm NSCLC. The brand aims to revolutionize the field of cancer treatment by specifically targeting the driver of the disease. 

In terms of efficacy, TAGRISSO® has shown remarkable results in clinical trials. For resectable EGFRm NSCLC, it has been found to reduce the risk of death by 51% compared to placebo. Moreover, in metastatic EGFRm NSCLC, TAGRISSO® has achieved a median overall survival of more than 3 years, surpassing other treatment options.

TAGRISSO® prioritizes patient safety, offering important information about potential adverse reactions and drug dosing. It has been used to treat over 45,000 patients in the United States alone, and its efficacy and safety have been well-documented in various studies.

By constantly pushing the boundaries of medical science, TAGRISSO® continues to provide hope and improve the lives of individuals battling EGFRm NSCLC.

## Industries

- 🏭 Chemical Industry _(under Heavy Industry and Engineering)_
- 🏭 Heavy Industry and Engineering

## Logos & icons

- logo _(primary)_ — PNG — [download](https://cdn.brandfetch.io/idEEeN1IeR/w/242/h/79/theme/dark/logo.png?c=1bxid64Mup7aczewSAYMX&t=1770329907802)

## Colors

| Name | Hex | Theme |
| --- | --- | --- |
| Black | #000000 | dark |
| Jordy Blue | #6bbaef | light |
| Di Serria | #d6964a | accent |

## Fonts

- LexiaLightItalic — asset _(custom)_
- Barlow — asset _(google)_

---

_Source: <https://brandfetch.com/tagrissohcp.com>_
_See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._